{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T19:52:10Z","timestamp":1783021930224,"version":"3.54.6"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T00:00:00Z","timestamp":1640217600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>The temporal association had been reported between vaccination and exacerbation of psoriasis, and episodes of psoriasis flare-up have recently been attributed to COVID-19 vaccines. We recruited 32 unimmunized controls and 51 vaccinated psoriasis patients, 49 of whom were under biological therapy, with regular clinic visits receiving a total of 63 shots of vaccines, including 30 doses of Moderna mRNA-1273 and 33 doses of AstraZeneca-Oxford AZD1222. Fifteen episodes of exacerbation attacked within 9.3 \u00b1 4.3 days, which is higher than two episodes in the control group (<jats:italic>p<\/jats:italic> = 0.047). The mean post-vaccination severity of the worsening episodes increased from PASI 3.1 to 8.0 (<jats:italic>p<\/jats:italic> &amp;lt; 0.001). Three patients showed morphologic change from chronic plaque-type to guttate psoriasis. Deterioration of psoriasis following COVID-19 vaccination was not associated with age, sex, disease duration, psoriatic arthritis, family history of psoriasis, history of erythroderma, current biologics use, comorbidities, vaccine types, human leukocyte antigen (HLA)-C genotypes, baseline PASI nor pre-vaccination PASI. For those who received two doses of vaccination, all but one patient aggravated after the first shot but not the second. The mechanism of psoriasis exacerbation in immunized individuals is unclear, but Th17 cells induced by COVID-19 vaccines may play a role. In the pandemic era, psoriasis patients and physicians should acknowledge the possibility of fluctuation of disease activity when vaccinated against COVID-19. Nevertheless, compared to a treatable dermatologic disease with rapid resolution of exacerbation, psoriasis patients who do not have contraindications to vaccination should benefit from COVID-19 vaccines in the prevention of severe COVID-19 infection and fatality.<\/jats:p>","DOI":"10.3389\/fmed.2021.812010","type":"journal-article","created":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T08:52:34Z","timestamp":1640249554000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":33,"title":["Exacerbation of Psoriasis Following COVID-19 Vaccination: Report From a Single Center"],"prefix":"10.3389","volume":"8","author":[{"given":"Yi-Wei","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsen-Fang","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,12,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"258430","DOI":"10.1155\/2015\/258430","article-title":"Possible triggering effect of influenza vaccination on psoriasis","volume":"2015","author":"Gunes","year":"2015","journal-title":"J Immunol Res."},{"key":"B2","doi-asserted-by":"publisher","first-page":"4347","DOI":"10.3390\/ijms20184347","article-title":"Risk factors for the development of psoriasis","volume":"20","author":"Kamiya","year":"2019","journal-title":"Int J Mol Sci."},{"key":"B3","doi-asserted-by":"publisher","first-page":"4785","DOI":"10.1016\/j.vaccine.2017.06.067","article-title":"Widespread psoriasis flare following influenza vaccination","volume":"35","author":"Shi","year":"2017","journal-title":"Vaccine."},{"key":"B4","doi-asserted-by":"publisher","first-page":"489","DOI":"10.5021\/ad.2013.25.4.489","article-title":"New onset guttate psoriasis following pandemic H1N1 influenza vaccination","volume":"25","author":"Shin","year":"2013","journal-title":"Ann Dermatol."},{"key":"B5","first-page":"37","article-title":"Psoriasis vaccinalis; report of two cases, one following B. CG vaccination and one following vaccination against influenza","volume":"35","author":"Raaschou-Nielsen","year":"1955","journal-title":"Acta Dermato Venereol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"103","DOI":"10.29784\/DS.200706.0003","article-title":"Clinical analysis of psoriatic inpatients-A 10-year retrospective study","volume":"25","author":"Yeh","year":"2007","journal-title":"Dermatol Sin"},{"key":"B7","doi-asserted-by":"publisher","first-page":"843","DOI":"10.3390\/vaccines9080843","article-title":"Influenza vaccination in psoriatic patients-epidemiology and patient perceptions: a german multicenter study (Vac-Pso)","volume":"9","author":"Kromer","year":"2021","journal-title":"Vaccines (Basel)."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e14684","DOI":"10.1111\/dth.14684","article-title":"Psoriasis flare after influenza vaccination in Covid-19 era: A report of four cases from a single center","volume":"34","author":"Mungu\u00eda-Calzada","year":"2021","journal-title":"Dermatol Ther."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e857","DOI":"10.1111\/jdv.17582","article-title":"Psoriasis exacerbation after COVID-19 vaccination: a report of 14 cases from a single centre","volume":"35","author":"Sotiriou","year":"2021","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e632","DOI":"10.1111\/jdv.17449","article-title":"Psoriasis flare-up associated with second dose of Pfizer-BioNTech BNT16B2b2 COVID-19 mRNA vaccine","volume":"35","author":"Krajewski","year":"2021","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.4103\/ds.ds_45_21.","article-title":"Psoriasis flare following ChAdOx1-S\/nCoV-19 vaccination in patients with psoriasis under biologic treatment","author":"Chao","year":"2021","journal-title":"Dermatol Sin."},{"key":"B12","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jaad.2021.03.092","article-title":"Cutaneous reactions reported after moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases","volume":"85","author":"McMahon","year":"2021","journal-title":"J Am Acad Dermatol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jdcr.2021.09.009","article-title":"Case of de novo nail psoriasis triggered by the second dose of Pfizer-BioNTech BNT162b2 COVID-19 messenger RNA vaccine","volume":"17","author":"Ricardo","year":"2021","journal-title":"JAAD Case Rep."},{"key":"B14","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1111\/bjd.16083","article-title":"HLA-Cw6 and psoriasis","volume":"178","author":"Chen","year":"2018","journal-title":"Br J Dermatol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s40257-020-00585-1","article-title":"HLA-Cw1 and Psoriasis","volume":"22","author":"Huang","year":"2021","journal-title":"Am J Clin Dermatol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.jaad.2003.09.014","article-title":"A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis","volume":"50","author":"Carlin","year":"2004","journal-title":"J Am Acad Dermatol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.1097\/CM9.0000000000001232","article-title":"Time to relapse after treatment withdrawal for different biologics used to treat plaque psoriasis","volume":"133","author":"Wang","year":"2020","journal-title":"Chin Med J."},{"key":"B18","doi-asserted-by":"publisher","first-page":"S171","DOI":"10.1016\/j.jaad.2005.10.029","article-title":"Relapse, rebound, and psoriasis adverse events: an advisory group report","volume":"54","author":"Carey","year":"2006","journal-title":"J Am Acad Dermatol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s13555-017-0187-0","article-title":"Guselkumab for the treatment of psoriasis: a review of phase III trials","volume":"7","author":"Nakamura","year":"2017","journal-title":"Dermatol Ther (Heidelb)."},{"key":"B20","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41591-020-01194-5","article-title":"T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1\/2 clinical trial","volume":"27","author":"Ewer","year":"2021","journal-title":"Nat Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.jaci.2017.07.004","article-title":"Psoriasis pathogenesis and the development of novel targeted immune therapies","volume":"140","author":"Hawkes","year":"2017","journal-title":"J Allergy Clin Immunol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1038\/jid.2011.458","article-title":"A single intradermal injection of IFN-\u03b3 induces an inflammatory state in both non-lesional psoriatic and healthy skin","volume":"132","author":"Johnson-Huang","year":"2012","journal-title":"J Invest Dermatol."},{"key":"B23","first-page":"163","article-title":"Serum interferon-gamma is a psoriasis severity and prognostic marker","volume":"84","author":"Abdallah","year":"2009","journal-title":"Cutis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.micinf.2020.04.005","article-title":"The potential role of Th17 immune responses in coronavirus immunopathology and vaccine-induced immune enhancement","volume":"22","author":"Hotez","year":"2020","journal-title":"Microbes Infect."},{"key":"B25","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/S2213-2600(20)30076-X","article-title":"Pathological findings of COVID-19 associated with acute respiratory distress syndrome","volume":"8","author":"Xu","year":"2020","journal-title":"Lancet Respir Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.jmii.2020.03.005","article-title":"TH17 responses in cytokine storm of COVID-19: an emerging target of JAK2 inhibitor Fedratinib","volume":"53","author":"Wu","year":"2020","journal-title":"J Microbiol Immunol Infect."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1002\/art.41734","article-title":"American college of rheumatology guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: version 1","volume":"73","author":"Curtis","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"221","DOI":"10.7499\/j.issn.1008-8830.2101133","article-title":"Efficacy and safety of COVID-19 vaccines: a systematic review","volume":"23","author":"Xing","year":"2021","journal-title":"Zhongguo Dang Dai Er Ke Za Zhi."},{"key":"B29","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jaci.2020.10.007","article-title":"Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based study","volume":"147","author":"Mahil","year":"2021","journal-title":"J Allergy Clin Immunol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e13383","DOI":"10.1111\/dth.13383","article-title":"A case of exacerbation of psoriasis after oseltamivir and hydroxychloroquine in a patient with COVID-19: will cases of psoriasis increase after COVID-19 pandemic?","volume":"33","author":"Kutlu","year":"2020","journal-title":"Dermatol Ther."},{"key":"B31","doi-asserted-by":"publisher","first-page":"e13632","DOI":"10.1111\/dth.13632","article-title":"Covid-19 and exacerbation of psoriasis","volume":"33","author":"Ozaras","year":"2020","journal-title":"Dermatol Ther."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1016\/j.jaad.2020.12.058","article-title":"National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: version 2-Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments","volume":"84","author":"Gelfand","year":"2021","journal-title":"J Am Acad Dermatol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.812010\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T08:52:39Z","timestamp":1640249559000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.812010\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,23]]},"references-count":32,"alternative-id":["10.3389\/fmed.2021.812010"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2021.812010","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,23]]},"article-number":"812010"}}